Fifth Third Bancorp
—Price / book
Market cap
—
Tangible equity
$16.71B
Price / tangible book
—
Price / book
—
Return on equity
11.6%
Return on assets
1.2%
Efficiency ratio
57.1%
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: FITB stock price vs AMRX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMRX's multiple
Needs AMRX P/E.
Implied fair value · at FITB's multiple
Needs FITB P/E.
Live quote
Price unavailable
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability edge
Asset efficiency lag
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: FITB FY 2025 (ended Dec 31, 2025) · AMRX FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity
$16.71B
Price / tangible book
—
Price / book
—
Return on equity
11.6%
Return on assets
1.2%
Efficiency ratio
57.1%
Price / book
Market cap
—
Tangible equity
-$1.23B
Price / tangible book
—
Price / book
—
Return on equity
-101.8%
Return on assets
2.0%
Efficiency ratio
—
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
FIFTH THIRD BANCORP · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
AMNEAL PHARMACEUTICALS, INC. · implied price per share
Bear
$3.25
Base
$3.82
Bull
$4.39
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.67x
-36.42x
Net debt / EBITDA
Leverage against operating earnings
-1.92x
4.47x
Cash and equivalents
Liquid reserves on the balance sheet
$36.03B
$282.03M
Total debt
Interest-bearing obligations outstanding
$14.52B
$2.58B
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.